the situation can be dealt with in a caring and understanding, but appropriate, manner.

Barrister
For ease of language, all doctors are ‘he’ in this response. The issues for the clinic doctor can be divided into two.

First, in respect of the patient, Mrs X:
1. Although, at present, this may appear as an isolated incident, advice should be given as to her contraceptive options for similar circumstances in the future.
2. Care will need to be taken in dealing with what the clinic doctor believes to be errors on the part of the GP. However, the clinic doctor is the specialist and the patient should be given the benefit of the specialist’s opinion. It is noteworthy that she has not chosen to return to her friend the GP to have the IUD removed. If the clinic doctor believes that serious errors were made, his duty to the patient must require him to give advice which reflects his opinion of those errors, thereby allowing the patient to make a more fully informed decision in the future.

Second, in respect of the GP:
1. On balance, the clinic doctor should not report the matter to the GP’s professional body. That judgement takes into account the following factors:
   - Although potentially serious in its way, the error on the part of the GP was not life threatening. In any event, the patient has not suffered long-term damage in this case.
   - The evidence of an error on the part of the GP comes entirely from the account given by the patient. The patient has shown no interest in having the error exposed to a wider audience. From the conduct of the patient to date, it would be safe to assume she has no interest in this matter being referred on for further investigation. Moreover, reporting the matter would conflict with the clinic doctor’s duty of confidentiality to the patient.
2. Further, the clinic doctor should not raise the matter with the GP directly. The considerations above apply here too. In addition, the nature of the patient’s relationship with the GP (and the circumstances in which the IUD came to be fitted) makes this course particularly difficult and inappropriate.

Discussion
The differences of opinion expressed indicate that no ‘right answer’ applies. It is clear that if you felt that action should be taken, you would need further information about the circumstances around the insertion of the IUD, and the consent of the patient to proceed. You may agree that, in view of the lack of harm caused, no action should be taken, but does this condone inadequate practice that might be repeated? What if the woman had developed a pelvic infection or had collapsed in the GP’s surgery following the IUD fitting? What would you have done faced with this situation? The Journal invites your comments.

Acknowledgement
The author would like to thank the panel members for their input. A listing of the individual panel members who have contributed to the Clinical Conundrum section of the Journal is published annually.

Journal Review

This is a double-blind, placebo-controlled study to evaluate the effect of mefenamic acid and placebo on controlling uterine bleeding in Depo-Provera users. The design of the study was good but the numbers were very small. Fifty-four women were recruited and six were dropped from the study. This left 23 in the mefenamic acid group and 25 in the placebo group. Mefenamic acid reduced the bleeding in the short term but the effect could not be shown with long-term use. Mefenamic acid might be of use for those women who cannot use oestrogen preparations. If it can produce an effect in the short term it might encourage women to continue with the method, especially after the first injection when there can be more bleeding irregularities than following later injections.

Reviewed by Judy Murty, DRCOG, MFFP
SCMO Contraceptive and Sexual Health Services, Leeds, UK


This is a report on Phase III trials for the new subcutaneous version of depot medroxyprogesterone acetate (DMPA-SC). There were two arms to the trial, an American population and a European/Asian population. It is interesting to note that only the European/Asian population had exclusions for risk of osteoporosis and enzyme-inducing drugs. The drug was administered 3 months for 1 year with the interval between injections being 91 ± 7 days.

Several of the results support what we already know in practice from the intramuscular version. Ovulation is suppressed in all women no matter what their weight. The body mass index of the study groups ranged from 14.7 to 57.7 and there were no pregnancies. There was no indication that DMPA-SC increases weight excessively. In the European group, the median weight gain was 1.0 (mean, 1.4 ± 3.6) kg and was not reported as a reason for stopping the method. The high incidence of amenorrhoea was confirmed at 55% after 1 year. This study suggests that the weight gain during the use of DMPA-SC may be less than that seen with the intramuscular version.

Reviewed by Judy Murty, DRCOG, MFFP
SCMO Contraceptive and Sexual Health Services, Leeds, UK


In an effort to increase availability, some states in the USA have introduced legislation to allow pharmacies to issue emergency contraception (EC). This randomised trial attempted to compare pregnancy rates and abortions, as well as sexually transmitted infection (STI) rates in women attending family planning clinics in the San Francisco Bay area. The women were allocated to one of three groups:

- Pharmacy access to EC
- Advance provision of three packs of levonorgestrel EC
- Clinic access as usual as a control group.

Unfortunately for the randomisation, local legislation was changed during the course of the study and the clinic access group would have been disadvantaged by being restricted to clinic access only. The control group had to be eliminated in the last half of the study, so that they could obtain EC from pharmacies if they wished. However, the study was powered to detect significant differences between the control group, clinic access and either of the two treatment groups. There was a low loss to follow-up of only 8% with almost equal losses from all three arms of the study. The women were young, mainly uninsured with low incomes, representing a high-risk group for unprotected sexual activity. The three groups reported similar rates of unprotected intercourse at 37.5%. Overall, only half (46.7%) of the women who had unprotected intercourse used EC, but a higher proportion of those who were in the ‘advanced provision’ group used EC (54.9%). Sexual risk factors, such as number of partners and frequency of intercourse, were similar across the three groups.

Proposals to widen access to EC have prompted worries that it might increase sexual risk-taking, both of STIs and of pregnancy (by abandoning regular contraception). There was no evidence in this study that women abandoned their regular contraception, or that there was any increase in STIs. There was no difference in pregnancy rates in the three groups, perhaps because the (low) use of EC was so similar in all the study groups with fairly high rates of unprotected intercourse. The increased use of EC in these populations that having to make an effort to obtain EC (via a pharmacy or clinic) adds a barrier to use. However, the main barriers to use seem to be the women’s lack of appreciation of their risk of pregnancy from acts of unprotected intercourse or their inability to take control of their fertility (leaving it to fate!). The study concluded that there should be no restriction of the provision of EC by pharmacies, in that it causes no harm. The study was unable to demonstrate that increasing availability of EC reduced pregnancy rates, because of the lack of use in around half the episodes of unprotected intercourse.

Reviewed by Gill Wakley, MD, MFFP
Visiting Professor in Primary Care Development, Staffordshire University and Freelance GP, Writer and Lecturer, Abergavenny, UK
Effect of mefenamic acid on controlling irregular uterine bleeding in DMPA users

Judy Murty

*J Fam Plann Reprod Health Care* 2005 31: 157
doi: 10.1783/1471189053629752

Updated information and services can be found at:
[http://jfprhc.bmj.com/content/31/2/157.1.citation](http://jfprhc.bmj.com/content/31/2/157.1.citation)

**Email alerting service**

*These include:*

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)